Fundraising footprint Domain Associates manages 2.4 billion in capital with a long history since 1985 and eight funds raised, indicating seasoned fundraising capability and a stable investment platform to approach for co-investment opportunities or LP/GP alignment discussions.

Life science focus Exclusive focus on life sciences spanning pharmaceuticals, diagnostics, and medical devices suggests potential for cross-sell of portfolio company services, co-investment deals, and tailored outreach to CEOs seeking VC partners with domain expertise.

Portfolio activity With involvement in over 250 portfolio companies and experience backing companies like Amgen and Adynxx, there is a strong foundation for deal sourcing collaboration, value-add partnerships, and potential secondary or advisory opportunities.

Global collaboration Recent investments in Russia and China through Rusnano and Beijing Elite highlight openness to international co-investments and strategic partnerships, presenting opportunities for market-entry support, regional syndication, and global funding rounds.

Early stage to growth signals Past and ongoing financings including Series A/B investments indicate readiness for both early-stage and growth-stage opportunities, suggesting targeted outreach across multiple rounds and scalable financing solutions aligned with portfolio needs.